Companies / Hungary
Teva Reconsiders Biotech Investment
February 2007 | FDI AlertIsraeli drugmaker Teva Pharmaceutical Industries is seriously considering pulling out of a US$100mn biotechnology investment in Hungary because of the country's new drug subsidy framework. Several other foreign and domestic firms are making similar threats, and BMI believes there is a strong possibility that Teva will invest elsewhere because we think the Hungarian government is unlikely to amend the medicine pricing
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
